Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06569147 · ClinicalTrials.gov registry record · Phase 1
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
A Phase 1 study of AL Amyloidosis, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT06569147: Recruiting Phase 1 study of AL Amyloidosis, sponsored by Brigham and Women's Hospital.
NCT06569147 is a Phase 1 study of AL Amyloidosis that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 49 participants, below the 421-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06569147, a Phase 1 study of AL Amyloidosis, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.
Primary Outcome
The recommended phase 2 dose determined in phase 1
Conditions Studied
Interventions
- DRUG Elranatamab
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 1 |
What NCT06569147 shows while recruiting
NCT06569147 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 421-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (88% lower).
The record links to 1 condition, with AL Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which Elranatamab is the first listed.
NCT06569147 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06569147 about?
NCT06569147 is a clinical study titled "Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis". This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.
What is the current status of trial NCT06569147?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2024-11-01. Estimated completion is 2029-09-01.
What conditions does trial NCT06569147 study?
This clinical trial studies the following conditions: AL Amyloidosis.
What interventions are being tested in trial NCT06569147?
The interventions under investigation include: Elranatamab (DRUG).
Who is sponsoring clinical trial NCT06569147?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06569147 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06569147's enrollment target sits among peer trials
49 8th of 15 higher than 8 of 15 other AL Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other AL Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
RECRUITING · Phase 1
-
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 1
-
Radioimmunoimaging of AL Amyloidosis
COMPLETED · Phase 1
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI